APONTIS PHARMA Revenue and Competitors

Monheim am Rhein,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • APONTIS PHARMA's estimated annual revenue is currently $20.7M per year.(i)
  • APONTIS PHARMA's estimated revenue per employee is $201,000

Employee Data

  • APONTIS PHARMA has 103 Employees.(i)
  • APONTIS PHARMA grew their employee count by -1% last year.

APONTIS PHARMA's People

NameTitleEmail/Phone
1
Head Tax /Accounting /Supply ChainReveal Email/Phone
2
Product ManagerReveal Email/Phone
3
Netzwerk ManagerinReveal Email/Phone
4
Medical ManagerReveal Email/Phone
5
Key Account Payer Access ManagerReveal Email/Phone
6
Regionaler VertriebsleiterReveal Email/Phone
7
PharmareferentinReveal Email/Phone
8
Assistenz MarketingReveal Email/Phone
9
Wissenschaftlicher Außendienst APONTIS-PHARMAReveal Email/Phone
10
Praxis- & PharmaberaterReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$53.7M26716%N/AN/A
#2
$53.1M26421%N/AN/A
#3
$69.1M34426%N/AN/A
#4
$22.1M110-10%N/AN/A
#5
$151.8M75511%N/AN/A
#6
$63.9M31813%N/AN/A
#7
$29.9M14913%N/AN/A
#8
$1.7M17-6%$114.3MN/A
#9
$6.8M34-6%N/AN/A
#10
$12.5M62-9%N/AN/A
Add Company

What Is APONTIS PHARMA?

APONTIS PHARMA is a pharmaceutical company focused on the commercialization of innovative pharmaceutical products to General Practitioners (GPs) and Internal Medicine Specialists in Germany. 
APONTIS PHARMA emerged in 2018 as a spin-off from a global pharmaceutical company UCB. APONTIS PHARMA builds on its long-standing UCB's and Schwarz Pharma's heritage.

keywords:N/A

N/A

Total Funding

103

Number of Employees

$20.7M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

APONTIS PHARMA News

2022-04-17 - DGAP-News: APONTIS PHARMA: START-Studie in wissenschaftlicher Publikation veröffentlicht - Kostenred.. Finanzen CH

DGAP-News: APONTIS PHARMA: START-Studie in wissenschaftlicher Publikation veröffentlicht - Kostenred.. Finanzen CH

2022-04-17 - APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy Yahoo Finance

APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of cardiovascular patients by Single Pill therapy Yahoo Finance

2022-02-22 - Paragon-backed Apontis Pharma announces IPO intention Unquote

Paragon-backed Apontis Pharma announces IPO intention Unquote

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$23.1M14924%N/A
#2
$59.4M2000%N/A
#3
$59M219-1%N/A
#4
$3.5M3696%N/A
#5
$3.5M4326%N/A